Hypertrophic Cardiomyopathy and Atrial Fibrillation: A Systematic Review and Meta-analysis of Anticoagulation Strategy.

Federico OliveriAntonella PepeAndrea BongiornoAlessandro FasolinoFrancesca Romana GentileSandra SchirinziDavide ColomboFederico BreviarioAlessandra GrecoAnnalisa TurcoMauro AcquaroLorenzo TuaLaura ScelsiStefano Ghio

Published in: American journal of cardiovascular drugs : drugs, devices, and other interventions (2023)

Compared with VKAs, a DOAC-based strategy might represent an effective and safe strategy regarding all-cause mortality, major/life-threatening bleeding complications, and TEs in HCM patients with concomitant AF. However, further prospective studies are necessary to reinforce a DOAC-based anticoagulation strategy in this population.

Keyphrases

atrial fibrillation
hypertrophic cardiomyopathy
direct oral anticoagulants
catheter ablation
left atrial
venous thromboembolism
left ventricular
oral anticoagulants
left atrial appendage
heart failure
percutaneous coronary intervention
risk factors
coronary artery disease
case control
acute coronary syndrome